Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11932643 Substituted heterocyclic inhibitors of PTPN11

Patent 11932643 was granted and assigned to Navire Pharma on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Zhijun Kang0

Jason Burke0

Timothy McAfoos0

Jason Cross0

Philip Jones0

Date of Patent

March 19, 2024

0

Patent Application Number

171667370

Date Filed

February 3, 2021

0

Patent Citations

US Patent 10954243 Substituted heterocyclic inhibitors of PTPN11

0

US Patent 7897607 Cyclic compounds

0

US Patent 9522881 Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)

0

US Patent 10280171 Heterocyclic inhibitors of PTPN11

0

US Patent 10851110 Heterocyclic inhibitors of PTPN11

0

US Patent 11104675 PTPN11 inhibitors

0

Patent Primary Examiner

0

CPC Code

0

Patent abstract

The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11932643 Substituted heterocyclic inhibitors of PTPN11

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool